hVIVO (LON:HVO) Trading Up 13% - Should You Buy?

Key Points

• hVIVO plc shares surged 13% in trading, reaching GBX 8 at their peak, with a significant increase in trading volume of 223% compared to the average.
• Analysts have mixed opinions on the stock, with Shore Capital lowering its price target from GBX 35 to GBX 25 while maintaining a "buy" rating, and a consensus target price of GBX 23.
• hVIVO reported a net margin of 25.96% and a return on equity of 47.93% in its latest earnings report, indicating strong profitability despite posting a loss of GBX (0.29) EPS for the quarter.

Shares of hVIVO plc (LON:HVO - Get Free Report) were up 13% during trading on Monday . The stock traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). Approximately 9,588,585 shares were traded during trading, an increase of 223% from the average daily volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HVO shares. Shore Capital reduced their price target on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating on the stock in a research report on Tuesday, September 23rd. Peel Hunt reissued an "add" rating and issued a GBX 21 target price on shares of hVIVO in a report on Tuesday, July 29th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, hVIVO has an average rating of "Buy" and a consensus target price of GBX 23.

hVIVO Stock Up 2.6%

The firm's 50 day simple moving average is GBX 9.24 and its 200 day simple moving average is GBX 11.96. The company has a market cap of £54.98 million, a price-to-earnings ratio of 1,038.96 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Sell-side analysts anticipate that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.